KLK2 and neoplasm: Accordingly, KLK2 was targeted with bispecific T-cell engagers that resulted in tumor cytotoxicity and with an α-radioconjugate 225Ac-anti-KLK2-mAb, which had anti-tumor activity in a xenograft model, similar to CAR-T cells.